Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Cognitive Disorder

Cognitive Disorder

9

Pipeline Programs↗

8

Active Trials↗

4

Companies Involved↗

Cognitive Disorder is an early-stage landscape with 9 programs across 4 companies.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

81/100

Attrition Rate

12/100

Pipeline

Programs by Phase

Preclinical7

Propofol

Fresenius Kabi USA, LLC

Methylene Blue

Provepharm SAS

Bupivacaine Liposome

Pacira Pharmaceuticals, Inc

Egb761

Ipsen

Intranasal Insulin

University Health Network, Toronto

Phase 1

No programs

Phase 22

Biological Check-up

University Hospital, Bordeaux

Lithium Treatment

VA Office of Research and Development

Phase 3

No programs

Approved

No programs

Analysis

Trial Status

26

clinical trials

Completed13 · 50%

Recruiting6 · 23%

Terminated3 · 12%

Not yet recruiting2 · 8%

Unknown status2 · 8%

Clinical Trials

Trial Activity

26 trials

Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency

Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT05600946·30 enrolled

Digital Dementia Registry Bavaria (digiDEM Bayern)

Recruiting·UUniversity of Erlangen-Nürnberg Medical School·N/A·NCT07721701·5,000 enrolled

Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials

Recruiting·—·N/A·NCT05888961·72 enrolled

Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)

Recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT06452147·1,860 enrolled

Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and Refusing Care.

Recruiting·UUniversity Hospital, Grenoble·Phase 2·NCT06638710·30 enrolled

A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder

Recruiting·—·Phase 1/2·NCT06776848·12 enrolled

Effects of Adaptive Difficulty Computerized Cognitive Training on Cognitive Function Improvement in Older Adults With Mild Cognitive Impairment

Not yet recruiting·CChina Medical University, China·Preclinical·NCT07753382·36 enrolled

Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial-

Not yet recruiting·UUniversity Hospital, Tours·Phase 2·NCT06382389·96 enrolled

Safety and Tolerability of MW151 Administered With Whole-brain Radiotherapy in Patients With Intracranial Metastases

Completed·IImmunoChem Therapeutics, LLC·Phase 1·NCT05417282·23 enrolled

EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

Completed· Ipsen logo

Ipsen·N/A·NCT02321475·54 enrolled

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders

Completed·MMateria Medica Holding·Phase 3·NCT04295681·246 enrolled

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

Completed·—·Phase 4·NCT01529749·48 enrolled

Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders

Completed·MMateria Medica Holding·N/A·NCT04370028·2,583 enrolled

Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials.

Completed·—·N/A·NCT04860414·45 enrolled

Study on Cognitive Disorders of Multiple Sclerosis

Completed·UUniversity Hospital, Caen·Phase 3·NCT01074619·90 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)